Table 1.
Baseline Characteristics of the Cohort Stratified by Cancer Treatment
| Total Cohort (N = 3,348) | Early Anthracycline Treatmenta (n = 1,675, 50.0%) | Late Anthracycline Treatmentb (n = 229, 6.8%) | Nonanthracycline Chemotherapy (n = 366, 10.9%) | No Chemotherapy (n = 1,078, 32.2%) | |
|---|---|---|---|---|---|
| Age, y | 76.1 ± 6.9 | 74.3 ± 5.9 | 74.3 ± 6.3 | 78.0 ± 7.1 | 78.6 ± 7.4 |
| Female | 1,628 (48.6) | 812 (48.5) | 120 (52.4) | 177 (48.4) | 519 (48.1) |
| Race | |||||
| Black | 181 (5.4) | 71 (4.2) | <11c | 21 (5.7) | 79 (7.3) |
| White | 3,058 (91.3) | 1,547 (92.4) | 212 (92.6) | >339 (>92.6)c | 957 (88.8) |
| Otherd | 109 (3.3) | 57 (3.4) | <11c | <11c | 42 (3.9) |
| Hispanice | 289 (8.6) | 143 (8.5) | 18 (7.9) | 28 (7.7) | 100 (9.3) |
| Stage | |||||
| I | 713 (21.3) | 311 (18.6) | 51 (22.3) | 71 (19.4) | 280 (26.0) |
| II | 755 (22.6) | 387 (23.1) | 62 (27.1) | 82 (22.4) | 224 (20.8) |
| III | 871 (26.0) | 493 (29.4) | 56 (24.5) | 106 (29.0) | 216 (20.0) |
| IV | 817 (24.4) | 402 (24.0) | 47 (20.5) | 90 (24.6) | 278 (25.8) |
| Unknown | 192 (5.7) | 82 (4.9) | 13 (5.7) | 17 (4.6) | 80 (7.4) |
| B symptoms | |||||
| Present | 1,197 (35.8) | 628 (37.5) | 114 (49.8) | 137 (37.4) | 411 (38.1) |
| Absent | 1,334 (39.8) | 672 (40.1) | 65 (28.4) | 139 (38.0) | 365 (33.9) |
| Unknown | 817 (24.4) | 375 (22.4) | 50 (21.8) | 90 (24.6) | 302 (28.0) |
| Heart failure/cardiomyopathyf | 437 (13.1) | 132 (7.9) | 25 (10.9) | 92 (25.1) | 188 (17.4) |
| Hypertension | 2,250 (67.2) | 1,106 (66.0) | 141 (61.6) | 276 (75.4) | 727 (67.4) |
| Diabetes | 1,045 (31.2) | 499 (29.8) | 65 (28.4) | 123 (33.6) | 358 (33.2) |
| Hyperlipidemia | 1,977 (59.1) | 1,062 (63.4) | 138 (60.3) | 239 (65.3) | 538 (49.9) |
| Coronary artery disease | 970 (29.0) | 415 (24.8) | 52 (22.7) | 159 (43.4) | 344 (31.9) |
| Prior myocardial infarction | 168 (5.0) | 62 (3.7) | <11c | 37 (10.1) | 61 (5.7) |
| Atrial fibrillation/flutter | 448 (13.4) | 163 (9.7) | 25 (10.9) | 79 (21.6) | 181 (16.8) |
| Valvular heart disease | 502 (15.0) | 226 (13.5) | 23 (10.0) | 79 (21.6) | 174 (16.1) |
| Peripheral vascular disease and carotid artery disease | 529 (15.8) | 210 (12.5) | 37 (16.2) | 78 (21.3) | 204 (18.9) |
| Ischemic stroke | 226 (6.8) | 80 (4.8) | 13 (5.7) | 26 (7.1) | 107 (9.9) |
| Chronic bronchitis/emphysema | 705 (21.1) | 335 (20.0) | 43 (18.8) | 90 (24.6) | 237 (22.0) |
| Dementia | 80 (2.4) | 23 (1.4) | <11c | <11c | 44 (4.1) |
| Moderate or severe renal disease | 272 (8.1) | 114 (6.8) | 17 (7.4) | 29 (7.9) | 112 (10.4) |
| Any prior cancer diagnosis | 529 (15.8) | 243 (14.5) | 38 (16.6) | 73 (19.9) | 175 (16.2) |
| Frailty (CFI19) | 0.18 ± 0.15 | 0.14 ± 0.11 | 0.14 ± 0.10 | 0.22 ± 0.14 | 0.24 ± 0.18 |
Values are mean ± SD or n (%).
CFI = claims-based frailty index; SEER = Surveillance, Epidemiology, and End Results.
Early anthracycline refers to those receiving their first anthracycline dose in the first 3 months after lymphoma diagnosis.
Late anthracycline refers to those receiving their first anthracycline dose 3 months or more after lymphoma diagnosis.
Cell counts with values <11 were suppressed to avoid reidentification of patients according to SEER-Medicare policy.
Other race in the SEER race recode includes: American Indian or Alaska Native and Asian or Pacific Islander.
Hispanic ethnicity defined by SEER. Hispanic ethnicity coding is independent of race coding.
Heart failure or cardiomyopathy was defined from International Classification of Diseases-9th Revision or International Classification of Diseases-10th Revision diagnostic codes; see “Methods” and Supplemental Appendix for details. The claims-based diagnostic codes may include some patients with cardiomyopathy but without the clinical syndrome of HF.